Table 1. Permanent polymer drug-eluting stent characteristics. DES name Stent platform Strut thickness (µm) Polymer Antiproliferative drug Cypher Select® Stainless steel 140 Polyethylene-co ...

Solaris Endovascular today announced its formation to develop solutions for dialysis access and treating peripheral artery ...

Abbott (NYSE:ABT) today announced data demonstrating the long-term effectiveness of its Esprit BTK drug-eluting stent.

A “bioadaptive” stent might circumvent the slow accumulation of target lesion failure that has been a consistent weakness of ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

More recently, drug-eluting stents (DESs) have emerged as the predominant percutaneous strategy in patients with coronary artery disease. This Review summarizes the knowledge on coronary stenting ...

So you can trust that a generic medication is going to work for you just as well as the brand name medication. So when a drug manufacturer wants to bring a new medication to the market ...

Abbott has delivered new, longer-term data from a clinical study of its dissolving stent for severe peripheral artery disease ...

You’ll usually need to continue dual antiplatelet drug therapy for a year after a drug-eluting stent placement and a month after a bare-metal stent placement. Drug-eluting stents are a newer ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of peripheral artery disease (PAD). The data, which was presented as a ...

For percutaneous coronary intervention (PCI) on de novo lesions, the DynamX bioadaptor not only matched drug-eluting stents ...

Non-drug eluting devices, such as bare-metal stents, catheters, and implantable medical devices, are widely used in procedures where drug elution is not necessary, or where a more mechanical or ...